Quick Answer
CRESCENT BIOPHARMA, INC. reported Total Revenue of $10.84 million for fiscal year 2025.
CRESCENT BIOPHARMA, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $10.84M | — | — | — | — | — |
| Revenue (ASC 606) | $10.84M | — | — | — | — | — |
| Net Income | -$153.94M -306.4% |
-$37.88M -2.7% |
-$36.90M +21.0% |
-$46.69M +26.4% |
-$63.43M -24.3% |
-$51.03M +11.9% |
| Diluted EPS | — | -$0.59 -1.7% |
-$0.58 +34.8% |
-$0.89 +27.6% |
-$1.23 -9.8% |
-$1.12 +16.4% |
| Total Assets | $240.29M +574.7% |
$35.62M -21.4% |
$45.32M -12.5% |
$51.81M -45.1% |
$94.35M -33.9% |
$142.83M -15.0% |
| Cash and Equivalents | $213.19M +513.2% |
$34.77M -16.8% |
$41.79M -12.7% |
$47.87M -47.0% |
$90.25M -34.1% |
$137.04M -13.4% |
| Stockholders Equity | $203.01M | $0.00 -100.0% |
$38.41M -10.5% |
$42.93M -47.4% |
$81.60M -36.4% |
$128.22M -16.8% |
| R&D Expense | $138.09M +868.4% |
$14.26M -29.0% |
$20.07M -29.3% |
$28.39M -40.2% |
$47.49M +5.7% |
$44.93M -4.5% |
| Operating Income | -$152.63M -281.2% |
-$40.04M -1.9% |
-$39.28M +17.1% |
-$47.40M +25.3% |
-$63.45M -23.2% |
-$51.51M +16.1% |
| Shares Outstanding | 27.56M +2605.3% |
1.02M -98.4% |
64.39M +18.4% |
54.38M +3.9% |
52.31M +6.7% |
49.02M +12.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2016 | $18.5K | — | -99.9% |
| Net Income | September 30, 2025 | -$24.61M | -835.3% | -12.9% |
| Diluted EPS | September 30, 2024 | -$0.15 | -7.1% | +6.3% |
| Total Assets | September 30, 2025 | $138.27M | +780.8% | -12.2% |
| Cash and Equivalents | September 30, 2025 | $133.26M | +826.0% | +2273.7% |
| Stockholders Equity | September 30, 2025 | $116.64M | +9058.6% | -16.2% |
| R&D Expense | September 30, 2025 | $20.35M | +722.8% | +68.4% |
| Operating Income | September 30, 2025 | -$25.89M | -883.8% | -23.1% |
| Shares Outstanding | September 30, 2025 | 13.89M | -78.5% | -0.0% |
- CRESCENT BIOPHARMA, INC. reported Total Revenue of $10.84 million for fiscal year 2025.
- CRESCENT BIOPHARMA, INC. showed an increase of +58516.2% in Total Revenue compared to the prior fiscal year.
- CRESCENT BIOPHARMA, INC. reported Revenue (ASC 606) of $10.84 million for fiscal year 2025.
- CRESCENT BIOPHARMA, INC. reported Net Income of -$153.94 million for fiscal year 2025.
- CRESCENT BIOPHARMA, INC. showed a decrease of -306.4% in Net Income compared to the prior fiscal year.
- CRESCENT BIOPHARMA, INC. reported Diluted EPS of $0.59 per share (loss) for fiscal year 2024.
- CRESCENT BIOPHARMA, INC. showed a decrease of -1.7% in Diluted EPS compared to the prior fiscal year.
- CRESCENT BIOPHARMA, INC. reported Total Assets of $240.29 million for fiscal year 2025.
- CRESCENT BIOPHARMA, INC. showed an increase of +574.7% in Total Assets compared to the prior fiscal year.
- CRESCENT BIOPHARMA, INC. reported Cash and Equivalents of $213.19 million for fiscal year 2025.
- CRESCENT BIOPHARMA, INC. showed an increase of +513.2% in Cash and Equivalents compared to the prior fiscal year.
- CRESCENT BIOPHARMA, INC. reported Stockholders Equity of $203.01 million for fiscal year 2025.
- CRESCENT BIOPHARMA, INC. showed an increase of +1411.5% in Stockholders Equity compared to the prior fiscal year.
- CRESCENT BIOPHARMA, INC. reported R&D Expense of $138.09 million for fiscal year 2025.
- CRESCENT BIOPHARMA, INC. showed an increase of +868.4% in R&D Expense compared to the prior fiscal year.
- CRESCENT BIOPHARMA, INC. reported Operating Income of -$152.63 million for fiscal year 2025.
- CRESCENT BIOPHARMA, INC. showed a decrease of -281.2% in Operating Income compared to the prior fiscal year.
- CRESCENT BIOPHARMA, INC. reported Shares Outstanding of 27.56 million shares for fiscal year 2025.
- CRESCENT BIOPHARMA, INC. showed an increase of +2605.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: